Gynecologic malignant tumors refer to malignant tumors occurring in the female reproductive system, including cervical cancer, endometrial cancer, ovarian cancer, vaginal cancer and vulvar cancer. Nowadays, surgery, radiotherapy, chemotherapy and other modalities are mostly used in the treatment of gynecological malignant tumors. The evaluation of the efficacy of tumor treatment is more important, so why do we need to evaluate the efficacy of tumor treatment? This is because: (1) tumor efficacy is the most important concern of patients; (2) tumor efficacy is the expected purpose of experimental drugs, treatment plans or new technologies, and the results are the basis for deciding whether they are worthy of further research and promotion; (3) tumor efficacy is the basis for clinicians to observe, for patients to continue their treatment, and for the continuation of the research project. To this end, we summarize the indicators of tumor efficacy evaluation and the efficacy of common gynecological malignant tumors, which are described as follows: I. Indicators for determining the efficacy of treatment 1. Recent efficacy: the change of tumor size is an important indicator of the objective efficacy of various anticancer therapies, and the evaluation of recent efficacy of tumor treatment will be compared with the size of the tumor at the end of the 4 weeks after the start of the treatment and before the treatment, which will be divided into: Complete remission (CR: Complete response) means that all of the tumor is completely resolved. Complete remission (CR: Complete Response) refers to the complete disappearance of all tumor masses and clinical manifestations of the tumor and lasts for at least 1 month; Partial remission (PR: Partial Response) refers to the measurable reduction of the sum of the two vertical diameters of the tumor by 50% compared with the baseline, and lasts for at least 1 month; Stable disease: the product of the two diameters of the tumor lesion shrinks by less than 50%, or increases by no more than 25%. Stable (SD: stable disease): less than 50% reduction in the product of the two diameters of the tumor lesions, or no increase of more than 25%, with no new lesions appearing, and lasting for more than 4 weeks; Progression: 25% increase in the product of the two vertical diameters of the tumor lesions from the minimum value, or the appearance of new tumors, or a significant progression of the evaluable disease. In addition, near-term efficacy is the sum of complete remission (CR) and partial remission (PR), which can be used to evaluate the near-term efficacy of tumor treatment, but only for measurable tumors. 2, Long-term efficacy: 5-year survival rate: it is the most commonly used indicator for evaluating the long-term efficacy of tumors in clinic, which refers to the proportion of a certain kind of tumor surviving for more than five years after various comprehensive treatments. After a certain tumor is treated, some of them may have metastasis and recurrence, and some of them may die because the tumor enters the advanced stage. Most of the metastases and recurrences occur within three years after treatment, accounting for about 80%, and a small portion occurs within five years after treatment, accounting for about 10%. Therefore, all kinds of tumors do not recur within five years after treatment, and the chances of recurrence are rare, so the five-year survival rate is often used to indicate the efficacy of various cancers. Within five years after surgery, it is necessary to consolidate treatment and have regular checkups to prevent recurrence, and even if there are metastasis and recurrence, it can be treated early. In addition, three-year survival rate and ten-year survival rate are also used to indicate the efficacy of treatment. Second, the efficacy of common gynecological malignant tumors 1, cervical cancer: cervical cancer is one of the most common malignant tumors among women, and occupies the first place among gynecological malignant tumors. Early stage cervical cancer adopts surgery as the main treatment, while cervical cancer above stage IIb adopts simultaneous radiotherapy as the main treatment. The prognosis of cervical cancer is good, the 5-year survival rate of early cervical cancer surgical treatment reaches about 90%; the 10-year survival rate reaches 79%; radiotherapy can be applied to all stages of cervical cancer, and the overall 5-year survival rate of stage I~IV can reach more than 50%. According to the data of World Health Organization in 2006, the 5-year survival rate of stage Ia1 is 98%, 95% of Ia2, 85% of Ib1, 75% of Ib2, 75% of IIa, 65% of IIb, 30% of IIIa, 30% of IIIb, 10% of IVa and <5% of IVb< font="">. In our hospital, the efficacy of radiotherapy for middle and advanced cervical cancer: the 5-year survival rate of stage IIb can reach 80%, and stage IIIb can reach 50%. 2.Endometrial cancer: endometrial cancer is a common malignant tumor of female reproductive system, and its incidence accounts for the first place of gynecological malignant tumors in economically developed countries. Most of the endometrial cancers develop slowly and clinical symptoms appear earlier, so it is easy to be detected at an early stage. Most of the cases are still confined to the uterus when diagnosed, so as long as the treatment program is reasonable, they can have a good prognosis. As long as the treatment plan is reasonable, patients can have a good prognosis. Early-stage endometrial cancer patients are given surgery-based treatment, while late-stage patients are given reasonable comprehensive treatment, including surgery, radiotherapy, chemotherapy, hormone therapy and so on. In the more than 40 years since the 1960s, the survival rate has been increasing year by year. According to the 5-year survival rate of endometrial cancer from 1999 to 2001 reported in the International Yearbook 26, 90.8% were in stage Ia, 91.1% in stage Ib, 78.8% in stage II, 66.2% in stage IIIa, 49.9% in stage IIIb, 57.3% in stage IIIc, 25.5% in stage IVa and 20.1% in stage IVb. Ovarian cancer: Ovarian cancer mortality rate is the highest among gynecological malignant tumors. Due to hidden onset and difficulty in early diagnosis, about 3/4 of the patients are already in advanced stage when they are diagnosed. About 3/4 of the patients are already in advanced stage when they are diagnosed. Its treatment is mainly based on surgery and supplemented by chemotherapy, and its prognosis is related to the histological type, clinical stage, grading, age and so on. The overall 5-year survival rate of ovarian epithelial cancer is 31%, 83.5% in stage Ia, 79.3% in stage Ib, 73.1% in stage Ic, 64.6% in stage IIa, 54.2% in stage IIb, 61.3% in stage IIc, 51.7% in stage IIIa, 29.2% in stage IIIb, 17.7% in stage IIIc and 14.3% in stage IV. Although the scope of surgery has been expanding and new chemotherapeutic agents and targeted drugs are constantly appearing, the therapeutic efficacy of ovarian epithelial cancer has not been improved, and about 70% of the patients will recur after treatment, less than 40% of the patients will be cured, and the 5-year survival rate still hovers around 30%~40%. In the past 20 years, advances in chemotherapy have significantly improved the therapeutic effect of ovarian germ cell tumors, reducing the mortality rate from 90% to 10%, and the 5-year survival rate is 95% in stage I, 70% in stage II, 60% in stage III, and 30% in stage IV. Most ovarian sex cord mesenchymal tumors are benign, and a few are low-grade or potentially malignant, with relatively good prognosis, e.g., the 10-year survival rate of granulosa cell tumors is 90%, and the 5-year survival rate of supporting cell-mesenchymal cell tumors is 70% to 90%. Ovarian junctional tumor is a kind of tumor between benign and malignant tumors of the ovary, with slow clinical growth, surgery is its main treatment and has a better prognosis. Some scholars have summarized 22 related literatures with a total of 953 patients, and the 5-year survival rate of patients with stage I was 99%, and that of patients with middle and late stage also reached 92%. The prognosis of young, early and plasma junction tumor patients is better. 4. Vaginal cancer: primary vaginal cancer accounts for about 1%~2% of gynecological malignant tumors. Radiotherapy is the treatment method for most vaginal cancers, which is applicable to all stages of vaginal cancers and can be combined with surgery and chemotherapy. The control rate of early vaginal cancer is as high as 90%. The overall 5-year survival rate of all stages of vaginal cancer is 35%~74%. At present, the more certain prognostic influencing factors are tumor stage and pathological type. Some scholars reported the 10-year survival rate of 212 patients with vaginal cancer, which could reach 80% in stage I, 48% in stage II, and only 38% in stage III. The prognosis of vaginal adenocarcinoma is obviously worse than squamous carcinoma. Vulvar cancer: vulvar cancer is a kind of rare malignant tumor, accounting for 3%~5% of gynecological malignant tumors, mostly occurring in postmenopausal elderly women. Its prognosis is related to tumor stage, grading, inguinal lymph node metastasis, age and other factors. The treatment of vulvar cancer is mainly based on surgery, supplemented by radiotherapy, and the overall 5-year survival rate can be up to 70%. Some scholars have summarized the prognosis of 502 patients with vulvar cancer, and the 5-year survival rates of stage I, II, III and IV are 91%, 76%, 65% and 29% respectively. The methods of evaluating the near-term efficacy and long-term efficacy of tumor treatment were introduced above, and the long-term efficacy of common gynecological malignant tumors was elaborated. In particular, it should be noted that the 5-year survival rate does not mean that the tumor will live for 5 years after treatment, but refers to the probability that the majority of patients can live for 5 years after treatment. And if the tumor survives after 5 years of treatment, there is generally little chance of recurrence. Finally, I wish the majority of gynecological tumor patients a speedy recovery, long-term survival and happiness!